Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Orqis Medical reports trial evaluation of percutaneous Cancion System

Orqis Medical : 02 April, 2008  (Company News)
Orqis Medical, a medical products company developing and marketing devices to treat heart failure, has released the company's Momentum Trial results that evaluated the percutaneous Cancion System in patients hospitalised with heart failure.
Barry Greenberg, MD, director, Advanced Heart Failure Treatment Program, University of California San Diego Medical Center, and national principal investigator for the Momentum Trial, presented the paper, ‘Efficacy and Safety of Continuous Aortic Flow Augmentation in Patients Hospitalised with Acute Decompensated Heart Failure: Results of the Momentum Trial’.

'While the Momentum Trial did not meet its primary composite efficacy endpoint, Momentum is a landmark study demonstrating that the Cancion System, in combination with conventional medical (drug) treatment, statistically significantly improved cardiac performance compared with drug treatment alone,' stated Dr Greenberg.

'There has been very little progress in identifying effective new approaches for treating patients with decompensated heart failure and the Cancion System provides physicians with a needed new treatment option.'

Ken Charhut, president and chief executive officer, Orqis Medical, stated, ' Momentum proved that the Cancion System significantly improves cardiac performance. Orqis' unique aortic flow therapy bridges the gap between medical management and more invasive procedures without ever touching the heart.'
The Cancion System is currently available in markets outside the USA.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo